Analytical Data
-
Gene name
HLA-A*02:01&B2M&KRAS G12V(KLVVVGAVGV) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & KRASG12V (KLVVVGAVGV)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&KLVVVGAVGV
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/KRAS G12V monomeric recombinant protein is of significant interest in the context of cancer immunology and therapeutic vaccine development. The KRAS protein, particularly the G12V mutation, is commonly associated with various aggressive cancers, including pancreatic, colorectal, and lung cancers. This mutation alters the normal function of the KRAS protein, leading to unregulated cellular proliferation and survival. HLA-A*02:01 is one of the most prevalent human leukocyte antigen (HLA) class I molecules that presents peptide antigens to CD8+ T cells, critically influencing immune recognition of tumors. The combination of HLA-A*02:01 and the KRAS G12V peptide (KLVVVGAVGV) creates a valuable tool for studying immune responses and developing targeted therapies, as it can help in identifying potential T cell responses against KRAS-mutant tumors. Moreover, the recombinant expression of this complex facilitates the study of T cell receptor (TCR) specificity, the design of peptide-based vaccines, and the exploration of novel immunotherapeutic strategies. Understanding the interactions between T cells, HLA molecules, and mutant peptides can ultimately lead to breakthroughs in personalized cancer treatment, aiming to enhance the efficacy and specificity of immune responses against tumors harboring KRAS mutations.
